Longitudinal increase of sTREM2 in CSF and its relationship with other biomarkers and cognition along the evolution of autosomal dominant Alzheimer’s disease

Therapeutic modulation of TREM2‐dependent microglial function provides an additional strategy to slow progression of Alzheimer’s disease (AD). Although studies on animal models suggest that TREM2 is protective, clinical biomarker studies reach different conclusions regarding TREM2 effect on tau pathology and its potential beneficial role in human AD. The longitudinal study of cerebrospinal fluid (CSF) soluble TREM2 (sTREM2) as a biomarker of TREM2 signalling during the evolution of autosomal dominant AD and its relationship with different biomarkers shed additional light on these controversies.